The HUGO-GT™ Grant Awards aims to support high impact preclinical research – in the fields of rare disease, ultra-rare disease, ophthalmology, neurology, and oncology − to develop next-generation humanized mouse models for effective disease R&D and gene therapy evaluations. If you are conducting research that could use humanized mouse models to substantiate your studies, we invite you to apply for a grant from the HUGO-GT™ Grant Awards!
Cyagen launched the HUGO-GT™ (Humanized Genomic Ortholog for Gene Therapy) program to develop full-length genomic sequence humanized mouse models with a broader range of intervention targets relevant to human genetic diseases. We employ our proprietary TurboKnockout-Pro technology to perform in-situ replacement of the targeted mouse endogenous gene, creating full-length genomic sequence humanized mouse models with a broader range of intervention targets.
The HUGO-GT™ Grant Awards offers researchers the opportunity to apply for a FREE pair of wild-type (wt) humanized mice from our standard HUGO-GT™ model service ($76,000 value). All applicants will also qualify for $15,000 off CRISPR point mutation (PM) services to investigate mutations of clinical significance based on our preexisting wt HUGO-GT™ humanized mouse strains.
Submit an online application form (below) to receive 50% off CRISPR PM services on existing wt HUGO-GT™ models ($15,000 value) and have a chance to win any of the wt HUGO-GT™ mouse model research grants ($76,000 value) offered by Cyagen Biosciences across the following award categories:
Applications will be reviewed on a rolling basis until all awards are selected, so early submissions have a greater chance for selection! As the awards for each Research Grant Award Category are granted, the application form for the respective category will close. Feel free to contact us if you have any questions regarding your submission.
One (1) Grand Prize (per Category, 5 total): Free standard wild-type (wt) HUGO-GT™ model service with up to 3 rounds of gene targeting with TurboKnockout-Pro ($76,000 value)
+
The grant award can be used as store credit towards Cyagen’s HUGO-GT™ model services and related downstream CRO services and/or CGT development platforms for model validation within 6 months of the award date of the grant. The award may be used for one (1) single standard HUGO-GT™ mouse model generation project (up to 3 rounds of gene targeting with TurboKnockout-Pro, $76,000 value) as described in the winning application(s). It cannot be used in combination with other coupons, discounts, or promotional offers.
All professionals in academic, non-profit, and not-for-profit biological research are eligible to apply, including graduate students, post-docs, principal investigators, and staff scientists. Please read the HUGO-GT™ Grant Awards Official Rules for full details regarding the grant competition.
Please visit our Application Guidelines for a quick outline of the requested materials and judging criteria for entries. Submit your application for the HUGO-GT™ Grant Awards by completing the following form:
Product Number | Product | Strain Background | Application |
---|---|---|---|
C001396 | B6J-hRHO | C57BL/6JCya | Retinitis Pigmentosa (RP), Congenital Stationary Night Blindness (CSNB), and other retinal diseases. |
C001410 | B6-htau | C57BL/6JCya | Frontotemporal Dementia (FTD), Alzheimer's Disease (AD), and other neurodegenerative diseases. |
C001418 | B6-hTARDBP | C57BL/6JCya | Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and other neurodegenerative diseases. |
C001427 | B6-hSNCA | C57BL/6NCya | Parkinson's Disease (PD). |
C001437 | B6-hIGHMBP2 | C57BL/6NCya | Spinal Muscular Atrophy with Respiratory Distress Type 1 (SMARD1) and Charcot-Marie-Tooth Disease Type 2S (CMT2S). |
C001495 | B6-hRHO-P23H | C57BL/6JCya | Retinitis pigmentosa (RP), congenital stationary night blindness (CSNB), and other retinal diseases research |
C001504 | B6-hSMN2(SMA) | C57BL/6NCya | Spinal muscular atrophy (SMA) |
I001128 | B6-hMECP2 | C57BL/6NCya | Rett Syndrome (RTT) |
I001124 | B6-hLMNA | C57BL/6NCya | Hutchinson-Gilford Progeria Syndrome (HGPS) |
C001398 | B6-hATXN3 | C57BL/6NCya | Spinocerebellar Ataxia Type 3 (SCA3) |
C001512 | B6-hTTR | C57BL/6NCya | Transthyretin Amyloidosis (ATTR) |
I001131 | B6-hSCN2A | C57BL/6NCya | Epilepsy |
I001132 | B6-hCFTR | C57BL/6NCya | Cystic Fibrosis (CF) |
C001525 | H11-Alb-hTTR*V50M | C57BL/6NCya | Transthyretin Amyloidosis (ATTR) |
I001130 | B6-hATP7B | C57BL/6NCya | Hepatolenticular Degeneration (HLD) |
IR1019 | SD-hGFAP Rat | Sprague-Dawley | Alexander disease (AxD), traumatic brain injury |
C001533 | B6-hINHBE | C57BL/6NCya | Obesity, metabolic disorders associated with improper fat distribution and storage |
C001538 | B6-hCOL7A1*c.6527dupC | C57BL/6NCya | Dystrophic Epidermolysis Bullosa (DEB) |
C001428 | B6-hCOL7A1 | C57BL/6NCya | Epidermolysis Bullosa (EB) |
C001546 | B6-hTGFBI | C57BL/6JCya | Corneal Dystrophy (CD) |
C001551 | B6-hABCA4 | C57BL/6JCya | Stargardt Disease (STGD) |
C001554 | B6-hUSH2A(E10-15) | C57BL/6JCya | Usher Syndrome (USH) |
C001555 | B6-hVEGFA | C57BL/6JCya | Age-related Macular Degeneration (AMD); Diabetic Retinopathy (DR); Corneal Neovascularization; Mechanisms of Tumorigenesis and Development, and Development of Antitumor Drugs. |
I001191 | B6-hFUS | C57BL/6JCya | Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration/Dementia (FTLD) |
I001181 | B6-htau*P301L | C57BL/6JCya | Frontotemporal Dementia (FTD), Alzheimer's Disease (AD), and other neurodegenerative diseases. |
I001182 | B6-htau*P301S | C57BL/6JCya | Frontotemporal Dementia (FTD), Alzheimer's Disease (AD), and other neurodegenerative diseases. |
I001203 | B6-hELP1 | C57BL/6NCya | Familial Dysautonomia (FD) |
I001179 | B6-hPCSK9 | C57BL/6NCya | Research on metabolic diseases such as hypercholesterolemia, atherosclerosis, and coronary heart disease; neurodegenerative diseases such as stroke and Alzheimer's disease; and tumor immunotherapy and autoimmune disease treatment. |
I001217 | B6-hCEP290 | C57BL/6JCya | Leber Congenital Amaurosis (LCA) |
I001218 | B6-hC5 | C57BL/6JCya | Age-related Macular Degeneration (AMD) |
I001133 | B6-hDMD (E49-53) | C57BL/6NCya | Duchenne Muscular Dystrophy (DMD) |
I001204 | B6-hDMD(E44-45) | C57BL/6NCya | Duchenne Muscular Dystrophy (DMD) |
I001208 | B6-hDMD(E44-45)*Del E44 | C57BL/6NCya | Duchenne Muscular Dystrophy (DMD) |
I001210 | B6-hABCA4*c.5461-10T>C | C57BL/6JCya | Stargardt disease (STGD); Cone-Rod Dystrophy (CRD); Retinitis Pigmentosa (RP) |
I001195 | DBA/1-hTNF | DBA/1 | Research on rheumatoid arthritis (RA); studies on the TNF-α signaling pathway; research on the pathogenesis and treatment of other TNF-α-related diseases |
I001190 | B6-hMECP2*T158M | C57BL/6NCya | Rett Syndrome (RTT) |
I001216 | B6-hSCN9A | C57BL/6NCya | Research on erythromelalgia, Dravet syndrome, small fiber neuropathy, and congenital insensitivity to pain; research on the pathogenesis of other neurological diseases and analgesic drugs. |
I001221 | B6-htau/hGLP-1R | C57BL/6Cya | Research on neurodegenerative diseases such as frontotemporal dementia (FTD) and Alzheimer's disease (AD); research on metabolic diseases such as obesity and type 2 diabetes; evaluation of the potential efficacy of GLP-1 receptor agonists (GLP-1RA) in Alzheimer's disease (AD). |
In response to these demands, Cyagen has developed novel whole genomic DNA humanized mouse models for accelerating gene therapy drug development: Humanized Genomic Ortholog for Gene Therapy HUGO-GT™ mice. The HUGO-GT™ next-generation humanized mouse models feature the following technical improvements to provide clinically relevant humanized mouse models more closely aligned with real-world biological mechanisms:
In addition to our mouse models, we offer Contract Research Organization (CRO) services in various fields, including ophthalmology, neuroscience, tumor immunology, and other disease areas. Our aim is to empower research on genetic diseases and facilitate the development of gene therapy drugs.
When replacing a mouse gene with the full genomic sequence of its human counterpart, the size of the DNA sequence can pose challenges for CRISPR-based approaches. In such cases, the use of homologous recombination in embryonic stem (ES) cells remains a viable and effective option.
Cyagen has leveraged the power of TurboKnockout-Pro, our proprietary high efficient ES targeting technology, to achieve in-situ replacement of the targeted mouse endogenous gene and successfully construct full-length genomic sequence humanized mouse models: HUGO-GT mice, that encompass a broader range of intervention targets.
HUGO-GT program is a comprehensive approach that combines the advantages of humanizing mouse genes through genomic replacement with the investigation of disease-causing mutations and potential gene therapy interventions.